Allergy/Imm Medical News about IBD

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression of IL-24, an Activator of the JAK1/STAT3/SOCS3 Cascade, Is Enhanced in Inflammatory Bowel Disease
Journal of Immunology, 06/30/09

Andoh A et al. - IL-24 did not modulate the proliferation of HT-29 cells, but significantly increased the mRNA expression of membrane-bound mucins. IL-24 derived from colonic SEMFs acts on colonic epithelial cells to elicit JAK1/STAT-3 activation and the expression of SOCS3 and mucins, supporting their suppressive effects on mucosal inflammation in IBD.

<< Previous
Systemic Reduction of Functionally Suppressive...

Next >>
Fusion Loop Peptide of the West Nile Virus Envelope Protein Is...

IBD drugs and cancer risk
JAMA, 11/18/09 Relevance Score: 87%

Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD
Gastroenterology Clinics of North America, 11/13/09 Relevance Score: 87%

Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease
Digestive Diseases and Sciences, 10/19/09 Relevance Score: 87%

Safety Profile of IBD Therapeutics: Infectious Risks
Gastroenterology Clinics of North America, 11/17/09 Relevance Score: 85%

Safety Profile of IBD: Lymphoma Risks
Gastroenterology Clinics of North America, 11/16/09 Relevance Score: 85%